Hims & Hers Health stock has a bearish daily structure, and the hourly chart confirms that bias.
Hims & Hers Health stock has a bearish daily structure, and the hourly chart confirms that bias. Oversold readings complicate the near-term picture, but they do not outweigh price being below all three daily exponential averages. The bullish case remains conditional on reclaiming resistance.
Summary
Key takeaways
- Hims & Hers Health stock was trading at $18.555 as of 13:03 ET, down 19.12% from the prior close of $22.94, with 1,180,216 shares traded.
- Price sits below the 20-session EMA at $26.25, the 50-session EMA at $27.85 and the 200-session EMA at $29.8.
- Daily RSI14 is 28.69, in oversold territory, while the daily MACD line at -1.68 is below its signal at -0.88.
- Hourly RSI14 is 18.18, with price below the hourly pivot at $18.68 and the hourly lower Bollinger band at $18.58.
- Daily ATR14 is $2.33, up from $2.16 on the preceding daily candle.
Hims & Hers Health stock: session price action
HIMS was trading at $18.555 as of 13:03 ET, down 19.12% from the previous close. On Tuesday, November 10, 2026, HIMS opened at $22.11 and traded between a low of $18.41 and a high of $22.47. Volume was 1,180,216 shares so far, and the previous close was $22.94 on November 9, 2026.
Earnings coverage frames the session
Coverage published before Tuesday’s open reported a third-quarter net loss and a subscriber decline from the prior quarter. Separately, coverage published on Monday, November 9, reported that the company lowered its full-year adjusted core profit expectations.
Meanwhile, a Seeking Alpha contributor’s piece published during Tuesday’s session carried a rating downgrade and argued that the valuation looked costly. That is a contributor’s assessment, rather than an independent technical signal.
Hims & Hers Health stock: the daily bearish case
The daily chart carries a bearish structure, with price below all three daily exponential averages. Price sits below the 20-session EMA at $26.25, followed by the 50-session EMA at $27.85 and the 200-session EMA at $29.8. This ordering supports the bearish bias. Price also sits below the daily lower Bollinger band at $21.7, with the mid-band at $27. Being outside the lower band is not evidence by itself of a reversal.
However, daily RSI14 stands at 28.69, in oversold territory. The daily MACD line is -1.68, below its signal at -0.88, with a negative histogram of -0.8. The signals carry mixed implications: RSI flags an oversold condition, while MACD still supports the bearish case.
Notably, daily ATR14 increased to $2.33 from $2.16 on the preceding daily candle, indicating greater measured volatility. Price is also below the daily first support at $21.89 and the daily pivot at $23.78. These reference levels come from the previous completed daily candle and apply to the current session.
Hourly confirmation and short-term timing
The hourly chart confirms the daily bearish bias, with price below all three hourly averages. Price sits below the 20-hour EMA at $22.66, the 50-hour EMA at $24.64 and the 200-hour EMA at $27.23. These averages are also bearishly aligned. Hourly RSI14 is 18.18, in oversold territory, while the MACD line at -1.68 is below its signal at -1.07.
At the same time, price is just below the hourly lower Bollinger band at $18.58 and the hourly pivot at $18.68. The hourly first resistance is $18.88, while first support is $18.39. These previous-hour reference levels define nearby resistance and support without changing the daily thesis.
For execution context, price sits above the 15-minute pivot at $18.52 but below first resistance at $18.63. It is also below the 20-period EMA at $20.02 on that timeframe. The 15-minute RSI14 is 14.7, in oversold territory. The 15-minute MACD histogram is -0.03, below zero. That is a limited counterpoint to the bearish higher-timeframe evidence, not a bullish confirmation.
Bullish and bearish conditions
A bullish scenario requires holding the 15-minute pivot at $18.52, then clearing 15-minute first resistance at $18.63. The next nearby hurdles are the hourly pivot at $18.68 and hourly first resistance at $18.88. For the daily case to become more constructive, price would need to reclaim the lower Bollinger band at $21.7 and first support at $21.89. The daily pivot at $23.78 would then be a further test.
In contrast, a break below $18.52 would undermine that near-term bullish sequence. The next references are 15-minute first support at $18.46, the session low at $18.41 and hourly first support at $18.39. A break below those levels would support the bearish case despite the oversold RSI readings.
Overall, Hims & Hers Health stock stands above the session low but below nearby hourly resistance and its daily averages. Daily ATR shows greater measured volatility. The unresolved question is whether oversold conditions can accompany resistance being reclaimed; the current chart does not yet confirm that outcome.
FAQ
Where is Hims & Hers Health stock trading in the current session?
HIMS was trading at $18.555 as of 13:03 ET, down 19.12% from the previous close of $22.94, with 1,180,216 shares traded so far.
What do the daily technicals show?
Price sits below the 20-session EMA at $26.25, the 50-session EMA at $27.85 and the 200-session EMA at $29.8. Daily RSI14 is 28.69, in oversold territory, while the daily MACD line at -1.68 is below its signal at -0.88.
What would a bullish scenario require?
Price would need to hold the 15-minute pivot at $18.52 and clear 15-minute first resistance at $18.63. The next hurdles are the hourly pivot at $18.68 and hourly first resistance at $18.88.
What are the nearby support levels?
The nearby references are 15-minute first support at $18.46, the session low at $18.41 and hourly first support at $18.39.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument. The analysis provided is not indicative of future results. Investing in financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.
Cryptonomist and the author hold no positions in the financial instruments mentioned and receive no compensation from the companies covered.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.
